It’s been more than six months since the outbreak of the novel coronavirus in Wuhan, China emerged and the epidemic has infected more than 12 million people worldwide and claimed 5,71,660 lives. Out of now, there are about 155 vaccines in several stages of trials to combat the spread of the infectious virus and 22 have entered the level of clinical trials.
While we all know about the global frontrunners in the race developing the vaccine including Moderna, CanSino, Inovio, BioNtech, Pfizer and AstraZeneca, back home AIIMS (All India Medical Sciences Institute) Patna, all are set to start human trials of India’s first coronavirus vaccine, Covaxine.
Bharat Biotech will, in collaboration with the National Institute of Virology (NIV), establish India’s first potential COVID vaccine ‘Covaxine’ for the unversed. The SARSCoV2 strain was isolated in NIV, Pune and transferred to Bharat Biotech to develop the vaccine candidate. This is an inactivated vaccine that uses the dead SARSCoV2 particles to stimulate the body through the production of protective antibodies to establish immunity against the virus. The candidate for the vaccine may develop an immune response during pre-clinical trials, according to Bharat Biotech.
Patna AIIMS to start human trials of Covaxine
ICMR (The Indian Medical Research Council) had selected 12 medical institutes across the nation including AIIMS Patna and Delhi to conduct the human trials. The Patna medical institute will launch the clinical trials on 18 volunteers aged between 18 and 55. It should be noted that while the medical institute had been approached by several people to participate in the trials, only 18 were chosen.
Both the 18 chosen volunteers must undergo a detailed medical check-up and the trial must start only after their findings have been carefully reviewed and given a go-ahead.
To conduct the first phase of the trial, the participants will be under observation for two to three hours after being administered the first dose. They will be given three doses of the vaccine candidate to complete the trial.